the leading one involves products from both in the united states, bristol meyers, and gillian. so it's hard to know, are they partners or are they competitors? and the prices would suggest they're more like partners than competitors. >> two comments i want to add. i think we're right thinking about this as an experiment, and thinking about how we can develop a better innovation system, not just for aids, but for health and beyond health for research more broadly. and i just wanted to reiterate that in thinking about the innovation system, there are a couple of other parts. the patent system will continue to play some role in, for instance, idea that's we haven't even thought about. in health, the price system is particularly well suited because we have a more well formulated notion of what we need. and, therefore, if it's particularly effective in that area, the mother areas where climate change, if it can be particularly effective, we know what we need in terms of the more efficient batteries. so there are certain areas where the prices are very well suited, other areas where

same thorough piewt -- part is that the legal coluges that you observe between company website bristol meyers and america, pfizer, gsk, abbott and roash all cross license their products in various ways until the hiv area. and or outside of the hiv area. and there are so often in bed with each other back and forth. and in some cases one company will sell the drug in the united states and other in europe or other countries. there might be a fixed dozed combination that involved products from both in the united states bristol meyers, and gill yet. so it's hard to know are they partners or competitors? and the prices would suggest they're more like partners than competitors. >> let me -- >> two comments i want to add. i think we're right thinking about this as an experiment an invasion and invasion. and thinking about how we can develop another innovation system for aids and beyond health for research for broadly. i want to reintegrate in think abouting the innovation system, there are a couple of other parts. the patent system will continue to play some role for instance, idea that's we haven't

reports they rejected $22 a share offer from bristol-meyer. they've received others from merck and santa fe. the spike on the stock went from flat to up about 6%. >> that is a spike indeed. thank you very much, brian shactman. next week it may be a short week, but it is long on news from housing to consumer confidence. there's a ton of economic data out there could impact your money. let's bring in julia coronado, chief economist at bnb and our very own rick santelli. julia, there's a lot of stuff going on next week. the payroll for may. what do you think next week's data will tell us about the state of the economy? >> i think frustratingly the data's going to tell us we're still stuck in neutral saying the u.s. economy is growing right around trend. the good news is it's remarkably stable. the bad news is there's not a lot of indications where shifting into a higher gear yet. >> is there any policymaking implications from what we're going to see next week, do you think, julia? or is stuck in neutral just essential policy neutral? >> i think f